Endoscopic Treatment Shows Promise for Chronic Radiation-Related Intestinal Bleeding

Pelvic radiotherapy saves lives by controlling cancers of the prostate, cervix, bladder and other organs, but the treatment can leave some patients with a delayed and debilitating intestinal injury. A new systematic review and meta-analysis suggests that endoscopic procedures can substantially reduce the persistent bleeding associated with chronic hemorrhagic radiation enteropathy, often without serious complications. The analysis, which combined evidence from 81 studies involving 2,626 patients, found that several techniques achieved high rates of bleeding control and visible healing. Argon plasma coagulation, the most extensively studied approach, produced clinical success in 95 percent of treated patients and endoscopic success in 97 percent. Radiofrequency ablation achieved 100 percent clinical and endoscopic success in the studies that used it, although it was evaluated in a much smaller group. The results offer reassurance for patients whose symptoms persist long after cancer treatment, while also highlighting the need for direct comparisons between the available technologies.

Chronic hemorrhagic radiation enteropathy generally develops at least three months after pelvic radiotherapy and may affect different sections of the intestine, including the rectum and colon. Patients can experience recurrent rectal bleeding, iron-deficiency anemia, fatigue and repeated dependence on blood transfusions. In severe cases, the condition can dominate daily life long after the original cancer has been treated. The injury begins with radiation-induced damage to DNA in intestinal epithelial cells and to the stem cells that normally replenish the lining of the gut. Over time, continuing inflammation and the effects of free radicals cause mucosal thinning, scarring of small arteries and obliterative endarteritis, a process in which blood vessels become narrowed or blocked. The resulting ischemia, or inadequate blood supply, promotes the formation of fragile telangiectasias—clusters of abnormally dilated blood vessels near the intestinal surface. These vessels can bleed repeatedly with minimal trauma. Changes in immune activity, intestinal nerve signaling and the gut microbiome may further sustain the disease, helping explain why it can be stubborn and progressive.

Supportive care and medications may help manage anemia or symptoms, but they often do not eliminate the abnormal blood vessels responsible for ongoing hemorrhage. Endoscopy offers a direct route to treatment: a flexible instrument allows clinicians to inspect the intestinal lining, identify bleeding lesions and apply energy or cooling precisely to the affected tissue. The new review was designed to assess not only whether bleeding improved, but also whether lesions appeared controlled during follow-up, whether patients stopped needing transfusions, whether bleeding returned and how frequently complications occurred. Researchers searched PubMed, EMBASE and the Cochrane Library through August 21, 2025, and followed the PRISMA 2020 framework for systematic reviews. Eligible studies included patients with chronic hemorrhagic radiation enteropathy who received an endoscopic intervention and reported at least one predefined outcome. Case reports, very small case series, reviews, animal studies and research protocols were excluded. The investigation was registered in PROSPERO before the evidence was assembled.

The strongest body of evidence concerned argon plasma coagulation, or APC, which was used in 2,255 of the patients included in the analysis. During APC, ionized argon gas carries a high-frequency electrical current from the endoscope to the tissue without requiring direct contact. The current heats and coagulates superficial vessels, while the flow of gas helps distribute the energy across a relatively broad area. This makes APC particularly useful for treating the diffuse vascular changes often seen after radiation exposure. Across the pooled studies, 95 percent of patients achieved clinical success, defined generally as a major improvement or complete resolution of bleeding symptoms such as hematochezia. Endoscopic success, meaning control of bleeding lesions as assessed visually, reached 97 percent. Patients’ mean hemoglobin concentration increased by 20.61 grams per liter, a clinically meaningful improvement for people who have been losing blood chronically. All patients who had required transfusions before treatment were reported as transfusion-free after treatment in the pooled analysis, although the number of patients contributing to that particular outcome may differ from the overall APC total.

APC also showed a pooled recurrence rate of 7 percent, suggesting that bleeding returned in a minority of patients who initially responded. Mild or moderate adverse events occurred in 7 percent, while no serious adverse events were reported in the aggregated APC evidence. Serious events were defined in the review as complications such as massive bleeding, perforation, obstruction or fistula. The absence of reported serious complications is encouraging, but it should not be interpreted as proof that the procedure carries no risk. The included studies varied in design, treatment schedules, patient characteristics and duration of follow-up. Some patients may have undergone multiple sessions, and the criteria used to define success were not identical across studies. In addition, uncommon complications can be difficult to detect in retrospective series or relatively small cohorts. Even so, the consistency of the overall results supports APC as an established endoscopic option, particularly where clinicians have extensive experience with the technique.

Radiofrequency ablation, or RFA, produced similarly striking results but was supported by a much smaller evidence base of 132 patients. RFA uses a controlled electrical current delivered through an electrode mounted on an endoscopic device. Instead of spraying energy over a wider field, the system applies a relatively uniform thermal injury to the superficial mucosa. The treated layer then heals, while abnormal vessels are destroyed or sealed. In the pooled analysis, clinical and endoscopic success rates were both 100 percent. The mean hemoglobin increase was 20.33 grams per liter, and 84 percent of previously transfusion-dependent patients became transfusion-free. Recurrence occurred in 8 percent, and mild or moderate adverse events were also reported in 8 percent. No serious adverse events were recorded. These findings suggest that RFA may be promising for symptom control and bleeding relief, but the apparent advantage over APC cannot be established from these numbers alone. RFA studies may have involved different patient populations, lesion patterns or follow-up periods, and the analysis did not compare the two procedures within the same randomized patient groups.

Other endoscopic technologies also showed substantial activity against radiation-related bleeding. Laser treatment achieved an 87 percent clinical success rate and a 91 percent endoscopic success rate in the available studies. Cryotherapy, which uses extreme cold to injure abnormal tissue and blood vessels, produced clinical success in 92 percent of patients and endoscopic success in 89 percent. Heater probe therapy, which applies direct thermal energy through a contact device, reached 100 percent for both clinical and endoscopic success in the reported evidence. Bipolar electrocoagulation, which delivers electrical energy between closely spaced electrodes to seal bleeding vessels, achieved a 94 percent clinical success rate and a 100 percent endoscopic success rate. These figures indicate that the biological target—fragile, superficial vessels in radiation-damaged mucosa—can be approached through several physical mechanisms. However, the varying number of patients studied for each modality means that success percentages should not be treated as a league table. A high rate based on a small cohort can be less reliable than a slightly lower rate supported by thousands of patients.

The statistical analysis used a random-effects model, an approach that assumes the true treatment effect may differ from one study to another rather than being identical everywhere. The researchers pooled proportions and calculated 95 percent confidence intervals, applying a Freeman–Tukey double-arcsine transformation to stabilize the variance of rates near zero or 100 percent. They also examined heterogeneity through meta-regression, leave-one-out sensitivity analyses and subgroup analyses. This methodology is useful when evidence comes from diverse observational studies, but it cannot remove the limitations of the underlying research. Most of the available investigations were not head-to-head trials, and the review often extracted data only from the endoscopic-treatment arm of comparative studies. Definitions of clinical and endoscopic success were also inherited from the original papers. In general, clinical success meant significant improvement or disappearance of bleeding, while endoscopic success meant visible hemostasis, but the exact thresholds and follow-up intervals could differ. Such variation can make pooled results appear more precise than the clinical evidence truly is.

The findings nonetheless have immediate relevance because chronic hemorrhagic radiation enteropathy can be difficult to treat and is increasingly encountered as more patients survive cancer for many years. By showing that endoscopic therapy can improve bleeding, raise hemoglobin levels and reduce transfusion requirements, the analysis strengthens the case for considering these procedures when conservative treatment fails. It also underscores the importance of matching the intervention to lesion distribution, tissue condition and local expertise. Thermal techniques can control superficial bleeding but require careful energy settings because radiation-damaged tissue may heal poorly. Clinicians must balance the need to eradicate abnormal vessels against the risk of deeper injury, ulceration or perforation. The review does not establish a single best procedure, and its authors emphasize that future research should directly compare APC, RFA, cryotherapy, laser treatment, heater probes and bipolar electrocoagulation in well-designed randomized trials. Such studies should standardize definitions, treatment sessions, follow-up duration, transfusion outcomes and adverse-event reporting. Until then, APC remains the best-studied choice, while RFA and the other modalities represent potentially valuable alternatives whose precise roles are still being defined.